The stock of Aurinia Pharmaceuticals Inc (TSE:AUP) gapped up by $0.02 today and has $14.52 target or 157.00% above today’s $5.65 share price. The 5 months technical chart setup indicates low risk for the $246.07M company. The gap was reported on Nov, 16 by Barchart.com. If the $14.52 price target is reached, the company will be worth $386.33M more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. About 199,004 shares traded hands or 108.49% up from the average. Aurinia Pharmaceuticals Inc (TSE:AUP) has risen 35.79% since April 12, 2016 and is uptrending. It has outperformed by 31.10% the S&P500.
More news for Aurinia Pharmaceuticals Inc (TSE:AUP) were recently published by: Businesswire.com, which released: “Aurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference” on November 10, 2016. 247Wallst.com‘s article titled: “Aurinia Pharmaceuticals Rises on Positive Mid-Stage Update” and published on November 16, 2016 is yet another important article.
Aurinia Pharmaceuticals Inc. is a Canada clinical-stage biopharmaceutical firm operating in the field of nephrology and autoimmunity. The company has a market cap of $246.07 million. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis . It currently has negative earnings. It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.